Exome Asset Management’s Elevation Oncology ELEV Stock Holding History

Exome Asset Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-110,353	Closed	-$40.5K	–	83
2025 Q2	$40.5K	Buy	+110,353	New	+$36.8K	0.03%	62
2024 Q3	–	Sell	-369,322	Closed	-$997K	–	69
2024 Q2	$997K	Hold	369,322	–	–	0.89%	38
2024 Q1	$1.89M	Buy	+369,322	New	+$1.2M	1.62%	23

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Exome Asset Management's ELEV Position: Q3 2025 in Review

Exome Asset Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 110,353 shares — an estimated $40.5K sold.

Exome Asset Management first reported a position in ELEV in Q1 2024 and held it in 3 quarters. The position peaked at $1.89M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Exome Asset Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Exome Asset Management sold 110,353 Elevation Oncology shares in Q3 2025, an estimated $40.5K.
Exome Asset Management first reported a position in Elevation Oncology in Q1 2024 and held it in 3 quarters.
Exome Asset Management's Elevation Oncology position peaked at $1.89M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.